| This week's sponsor is RAPS. | | | |
Today's Rundown Innate hopes dosing tweak will save BMS-partnered lirilumab Regeneron scraps Eylea combination after phase 2 setbacks Biogen inks Alkermes deal to defend multiple sclerosis turf [Sponsored] What makes a modern-day biotech? Merck places £1B bet on R&D in post-Brexit Britain Riding on booming drug sales, AstraZeneca forms $133M China joint venture After rare disease failure, Biohaven pushes the gas on oral migraine drug Merck will delay filing Ebola vaccine for approval until 2018, company confirms More bad news for Bayer/Nektar inhaled antibiotic alliance Featured Story | | | Monday, November 27, 2017 Innate Pharma has admitted that it can’t see an obvious way to bring its cancer antibody lirilumab forward in development after it flunked a second clinical trial. |
|
|
| This week's sponsor is Charles River. | | | |
Top Stories Monday, November 27, 2017 Regeneron has halted development of an ophthalmic combination of nesvacumab and Eylea. The decision follows data from two phase 2 trials that tested angiopoietin 2 antibody nesvacumab in combination with Eylea. Monday, November 27, 2017 Biogen has struck a deal to protect its blockbuster multiple sclerosis franchise Tecfidera from the threat of Alkermes’ ALKS 8700. The deal gives Biogen the exclusive worldwide rights to a candidate designed to match the efficacy and better the safety of a cornerstone of its commercial operation. Monday, November 27, 2017 Blue Latitude Health interviews 6 biotech leaders to reveal the commercial challenges and opportunities in 2018 and beyond, including big data, FDA approvals, combination therapies, empowered patients and the skills crisis. Monday, November 27, 2017 Merck is set to invest about £1 billion ($1.3 billion) to open a drug discovery facility in London. The decision is a vote of confidence in the United Kingdom at a time when it is struggling to convince companies they will thrive in the country after Brexit. Monday, November 27, 2017 As fellow Big Pharma GlaxoSmithKline, Eli Lilly and Pfizer are scaling back some of their activities in China, AstraZeneca is doubling down on the market through a new drug development joint venture with a state-backed private equity firm. Monday, November 27, 2017 Biohaven Pharma has completed patient recruitment in a late-stage trial of migraine candidate rimegepant, which is looking like its best pipeline prospect after its rare-disease candidate hit a snag last month. Tuesday, November 21, 2017 Despite a frantic effort to rush Ebola vaccines through testing during a deadly epidemic, Merck & Co. will fall short of its goal to file its candidate for FDA approval this year, the company confirmed Tuesday. Merck is now aiming for next year. Monday, November 27, 2017 Just days after their lead drug-device combination was voted down by FDA advisors, Nektar and Bayer have been hit by a phase 3 failure in another partnered program. Resources Sponsored by: Reprints Desk SO CLOSE AND YET SO FAR. Is that how many documents seem to you? Getting what you want—when, where, and how you want it—can be a real pain. That’s why we created this concise guide to getting around the obstacles that stand between you and the information your organization needs. Download the whitepaper to learn more. Presented By: Covance Global clinical trials are the trend and gaining in popularity, but running a global trial is not a straightforward process. This white paper explores some of the challenges associated with global clinical trials and considerations for ensuring that the collected data comply with the trial's overall objectives. Sponsored by: Veeva Systems See the results from one of the largest, most in-depth surveys of clinical data management professionals on data management practices, performance, and challenges. Sponsored by: Veeva Systems Gain a complete, real-time view of quality and streamline operations. Incorporate partners into processes for critical oversight and 30% greater efficiency, and transform cross-functional processes like change control. Presented by: DSM Biomedical Discover DSM's Dyneema Purity® membrane, an effective and efficient material to construct stent grafts used in minimally invasive surgeries to treat both cardiovascular and peripheral arterial diseases. Sponsored by: ePharmaSolutions As clinical trials become more complex, safety document distribution to investigative sites has reached the point that demands a solution. Sponsored by: Ashfield Healthcare December 5, 2017 | 2pm EST / 11am PST Join this webinar to learn methods that maintain and build sales momentum despite turnover. Sponsored by: Veeva CROs are leading an industry wide shift to modernize clinical systems and clinical trial processes. Presented By: Charles River Join us as we discuss how Charles River Celsis® helped Labor L+S AG validate a 7-day membrane filtration sterility test using existing protocols. Presented By: Catalent Learn how Catalent Biologics is paving the way for flexible biologics development and manufacturing through advanced technologies and fully integrated multi-product facility. Presented By: Catalent Download the eBook to get articles from various Elsevier journals highlighting developments in ADC technology. Presented By: Catalent Learn how cell development and process scale-up can be optimized for antibodies requiring additional processing. Sponsored By: RTI Health Solutions In this webinar, we will introduce the rapidly-evolving within-subject clinical trial (WSCT) methods for early phase evidence generation that require fewer people, less time, and usually less funding than traditional early phase methods. BioBasics: Biotech for the Non-Scientist November 30-December 1, 2017 | Boston, MA FierceBiotech Executive Breakfast: Get Good Science and the Money will Follow January 9, 2018 | San Francisco, CA BIO Asia International Conference March 19-20, 2018 | Tokyo, Japan Molecular Med Tri-Conference February 11-16, 2018 | San Francisco, CA | 